APEX1 and Kaposi's sarcoma: (3) Since KSHV is heavily dependent on APE1-regulated cell proliferation and survival pathways for viral replication and pathogenic feature development, APE1 has been validated to be an excellent target for anti-KSHV and KS therapy.